Overview
Switching from Saxenda (liraglutide) to Wegovy (semaglutide) is one of the more common transitions in the anti-obesity medication space. Both are GLP-1 receptor agonists manufactured by Novo Nordisk, but they differ significantly in dosing frequency, efficacy in clinical trials, and practical convenience. Many patients and healthcare providers consider this switch an upgrade within the same drug class.
Always switch medications under the guidance of your healthcare provider. Do not adjust doses without consulting your prescriber.
Why Patients Consider Switching
The clinical and practical differences between Saxenda and Wegovy make this switch appealing for several reasons:
Greater efficacy in clinical trials: The SCALE trial found that liraglutide 3.0 mg (Saxenda) produced a mean weight loss of approximately 8% of body weight over 56 weeks. The STEP 1 trial found that semaglutide 2.4 mg (Wegovy) produced approximately 14.9% over 68 weeks. While these trials used different populations and durations, and individual results vary, the data suggest semaglutide generally produces greater weight reduction.
Weekly vs. daily injections: Saxenda requires daily injection, while Wegovy is administered once weekly -- reducing injection frequency from 365 to 52 times per year.
Sustained action: Semaglutide's longer half-life (approximately 7 days vs. 13 hours for liraglutide) provides more consistent drug levels and more stable appetite suppression throughout the week.
Transition Approach
Although Saxenda and Wegovy are both GLP-1 receptor agonists, they contain different active ingredients (liraglutide and semaglutide, respectively). The transition is not simply a dose adjustment -- it is a change to a different medication that requires its own titration schedule.
Stopping Saxenda: Your healthcare provider will advise on when to discontinue Saxenda. Because liraglutide has a short half-life, it clears from the body relatively quickly.
Starting Wegovy: The standard Wegovy titration schedule begins at 0.25 mg once weekly and increases gradually:
- Weeks 1-4: 0.25 mg weekly
- Weeks 5-8: 0.5 mg weekly
- Weeks 9-12: 1.0 mg weekly
- Weeks 13-16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (maintenance dose)
This titration takes approximately 16 to 20 weeks to reach the full maintenance dose. Your healthcare provider may adjust this schedule based on your individual response and tolerability.
Timing the switch: Typically, the first Wegovy injection is scheduled shortly after the last Saxenda injection. Your provider will determine the exact timing. Because liraglutide clears the body within about a day, there is generally no prolonged overlap between the two medications.
What to Expect
Early weeks may feel like a step back: Because you are starting Wegovy at a very low dose (0.25 mg) after being on a full dose of Saxenda (3.0 mg), you may notice a temporary reduction in appetite suppression during the initial titration weeks. This is a normal part of the transition and does not indicate that Wegovy will be less effective long-term.
Gastrointestinal effects: Nausea, vomiting, diarrhea, and constipation are common side effects of both medications. Even if you had adjusted to these effects on Saxenda, they may recur during Wegovy titration, particularly at each dose increase. For most patients, these effects are mild to moderate and improve within days to weeks at each dose level.
Injection technique: Wegovy uses a prefilled pen device with a different design than the Saxenda pen. Your healthcare provider or pharmacist can demonstrate the proper technique. The injection sites (abdomen, thigh, or upper arm) are the same.
Weight trajectory: Some patients may experience a brief period of weight stabilization or modest regain during early titration. As the Wegovy dose increases toward the maintenance level, appetite suppression and weight loss typically resume and may ultimately exceed what was achieved on Saxenda.
Important Reminders
- Do not switch medications or adjust doses without consulting your healthcare provider
- Complete the full Wegovy titration schedule to minimize side effects and optimize outcomes
- Report persistent or severe gastrointestinal symptoms to your provider, who may adjust the titration pace
- Continue following dietary and physical activity recommendations during the transition
- Keep all scheduled follow-up appointments, particularly during the titration period
- If you have type 2 diabetes, discuss blood glucose monitoring plans with your provider, as GLP-1 medications can affect blood sugar levels
Related Pages
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.